ADNAST(Anastrazole)
Therapeutic class: Aromatase Inhibitor
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
1 mg Tablets
1 mg:- A strip of 10 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
